Biography and Research Information
OverviewAI-generated summary
Oscar Zuniga's research focuses on understanding and overcoming therapeutic resistance in various cancers, particularly pancreatic, thyroid, and rectal cancers. His work investigates molecular signaling pathways that contribute to radioresistance, such as the RAS-RAF-miR-296-3p axis, which has been shown to increase Rad18 expression. Zuniga also explores strategies to enhance radiosensitivity, including targeting specific enzymes like SETD2 in rectal cancer and homologous repair mechanisms in pancreatic cancer. His recent publications also examine the role of dietary interventions, like methionine restriction, in improving treatment outcomes and protecting healthy tissues during radiation therapy. Zuniga collaborates with researchers at the University of Arkansas for Medical Sciences, including Henrique Rodrigues, Lokesh Akana, Nükhet Aykin‐Burns, and Isabelle Racine Miousse.
Metrics
- h-index: 2
- Publications: 7
- Citations: 7
Selected Publications
-
Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction (2025)
-
RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers (2024)
-
Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer (2024)
-
Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers (2023)
-
Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer (2023)
-
205 Targeting Homologous Repair to Overcome Genotoxic Therapy Resistance in Pancreatic Cancer (2022)
Collaboration Network
Top Collaborators
Adam R. Wolfe
University of Arkansas for Medical Sciences (US)
7 shared publications
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
- 205 Targeting Homologous Repair to Overcome Genotoxic Therapy Resistance in Pancreatic Cancer
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
Showing 5 of 7 shared publications
Henrique Rodrigues
University of Arkansas for Medical Sciences
4 shared publications
In database
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Lokesh Akana
University of Arkansas for Medical Sciences
3 shared publications
In database
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- 2646: Enhancing Radiosensitization by Targeting SETD2 in Rectal Cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Sarita Garg
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Nükhet Aykin‐Burns
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Isabelle R. Miousse
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Haihua Feng
City of Hope (US)
2 shared publications
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
Henrique Rodrigues
2 shared publications
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
- 2646: Enhancing Radiosensitization by Targeting SETD2 in Rectal Cancer
Daniel E. Eldridge
Winthrop Rockefeller Foundation (US)
2 shared publications
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
Changxian Shen
City of Hope (US)
2 shared publications
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
Terence M. Williams
City of Hope (US)
2 shared publications
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Ras-Raf-Mir-296-3p Signaling Axis Increases Rad18 Expression to Augment Radioresistance in Pancreatic and Thyroid Cancers
Saaimatul Huq
University of Arkansas for Medical Sciences (US)
2 shared publications
- 2646: Enhancing Radiosensitization by Targeting SETD2 in Rectal Cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Kirk L. West
University of Arkansas for Medical Sciences
1 shared publication
In database
- 205 Targeting Homologous Repair to Overcome Genotoxic Therapy Resistance in Pancreatic Cancer
Justin Leung
University of Arkansas for Medical Sciences (US)
1 shared publication
- 205 Targeting Homologous Repair to Overcome Genotoxic Therapy Resistance in Pancreatic Cancer
Stetson Van Matre
University of Arkansas for Medical Sciences
1 shared publication
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
Similar Researchers
Based on overlapping research topics
Robin Eluvathingal
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Diet and metabolism studies
Henrique Rodrigues
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Diet and metabolism studies
Stetson Van Matre
University of Central Arkansas
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Diet and metabolism studies
Lokesh Akana
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Diet and metabolism studies
Lee, Seongok
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
K Ellis
University of Arkansas – Fort Smith
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Neoplasms